About EirGen Pharma
EirGen Pharma is a company based in Waterford (Ireland) founded in 2005 was acquired by Opko Health in May 2015.. EirGen Pharma has raised $24 million across 1 funding round from investors including Opko Health and SPIMACO. EirGen Pharma offers products and services including CDMO Services, CMO Services, and CPO Services. EirGen Pharma operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Waterford, Ireland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24 M (USD)
in 1 rounds
-
Latest Funding Round
$24 M (USD), Series B
Mar 24, 2012
-
Investors
Opko Health
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Opko Health
(May 05, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EirGen Pharma
EirGen Pharma offers a comprehensive portfolio of products and services, including CDMO Services, CMO Services, and CPO Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
End-to-end development and manufacturing of pharmaceutical products
Manufacturing of high-potency drugs for partners
Packaging solutions for pharmaceutical items globally
Funding Insights of EirGen Pharma
EirGen Pharma has successfully raised a total of $24M through 1 strategic funding round. The most recent funding activity was a Series B round of $24 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $24.0M
-
First Round
First Round
(24 Mar 2012)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2012 | Amount | Series B - EirGen Pharma | Valuation | SPIMACO |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EirGen Pharma
EirGen Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Opko Health and SPIMACO. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tablets, capsules, syrups, creams, and injectables are manufactured.
|
Founded Year | Domain | Location | |
|
Molecular diagnostic products for prostate cancer assessment are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EirGen Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EirGen Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eirgen Pharma Comparisons
Competitors of EirGen Pharma
EirGen Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| domain | founded_year | HQ Location |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| domain | founded_year | HQ Location |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| domain | founded_year | HQ Location |
APIs and finished products are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| domain | founded_year | HQ Location |
APIs and peptides are developed and manufactured by Asymchem.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eirgen Pharma
Frequently Asked Questions about EirGen Pharma
When was EirGen Pharma founded?
EirGen Pharma was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Where is EirGen Pharma located?
EirGen Pharma is headquartered in Waterford, Ireland.
Is EirGen Pharma a funded company?
EirGen Pharma is a funded company, having raised a total of $24M across 1 funding round to date. The company's 1st funding round was a Series B of $24M, raised on Mar 24, 2012.
What does EirGen Pharma do?
EirGen Pharma focuses on the development, registration and commercial manufacture of high potency, high barrier to entry solid dose products for the global pharmaceutical market. It is licensed to manufacture oncology, cytotoxic, steroidal and immunosuppressant molecules. It has an Investigational Medicinal Products (IMP) licence for the manufacture of clinical trial materials and a Manufacturing Licence for commercial manufacturing and packaging. It provides services for Clinical trial management, drug formulation development, generic formulation development, cytotoxic product production and contract manufacture of a wide range of chemical entities. In May 2015 EirGen Pharma was acquired by OPKO Health. The companys facilities are approved by the FDA (US), PMDA (Japan), EMA (Europe) and HPRA (formerly the Irish Medicines Board) .
Who are the top competitors of EirGen Pharma?
EirGen Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
What products or services does EirGen Pharma offer?
EirGen Pharma offers CDMO Services, CMO Services, and CPO Services.
Who are EirGen Pharma's investors?
EirGen Pharma has 2 investors. Key investors include Opko Health, and SPIMACO.